KA
DGX icon

Kintegral Advisory’s Quest Diagnostics DGX Stock Holding History

Kintegral Advisory’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Sell
11,984
-531
-4% -$103K 0.22% 109
2025
Q4 		$2.17M Sell
12,515
-343
-3% -$62.5K 0.18% 119
2025
Q3 		$2.45M Sell
12,858
-57
-0.4% -$10.1K 0.21% 114
2025
Q2 		$2.32M Sell
12,915
-20
-0.2% -$3.47K 0.21% 115
2025
Q1 		$2.19M Sell
12,935
-43
-0.3% -$7.06K 0.22% 115
2024
Q4 		$1.96M Sell
12,978
-605
-4% -$94.1K 0.18% 126
2024
Q3 		$2.11M Sell
13,583
-178
-1% -$26.6K 0.19% 127
2024
Q2 		$1.88M Buy
13,761
+2,374
+21% +$325K 0.18% 127
2024
Q1 		$1.52M Sell
11,387
-35
-0.3% -$4.54K 0.15% 132
2023
Q4 		$1.57M Sell
11,422
-72
-0.6% -$9.47K 0.17% 128
2023
Q3 		$1.4M Sell
11,494
-7
-0.1% -$933 0.17% 128
2023
Q2 		$1.62M Hold
11,501
– – 0.19% 118
2023
Q1 		$1.63M Sell
11,501
-618
-5% -$88.4K 0.21% 118
2022
Q4 		$1.9M Sell
12,119
-623
-5% -$89.5K 0.25% 116
2022
Q3 		$1.56M Hold
12,742
– – 0.22% 114
2022
Q2 		$1.69M Buy
12,742
+270
+2% +$36.8K 0.22% 109
2022
Q1 		$1.71M Buy
12,472
+279
+2% +$38.9K 0.19% 116
2021
Q4 		$2.11M Hold
12,193
– – 0.22% 110
2021
Q3 		$1.77M Hold
12,193
– – 0.21% 116
2021
Q2 		$1.61M Hold
12,193
– – 0.19% 124
2021
Q1 		$1.56M Hold
12,193
– – 0.2% 121
2020
Q4 		$1.45M Hold
12,193
– – 0.2% 122
2020
Q3 		$1.4M Sell
12,193
-392
-3% -$46.3K 0.21% 110
2020
Q2 		$1.43M Hold
12,585
– – 0.23% 103
2020
Q1 		$1.01M Buy
12,585
+1,408
+13% +$146K 0.2% 123
2019
Q4 		$1.19M Hold
11,177
– – 0.22% 119
2019
Q3 		$1.2M Hold
11,177
– – 0.24% 116
2019
Q2 		$1.14M Hold
11,177
– – 0.23% 122
2019
Q1 		$1M Buy
11,177
+8,661
+344% +$751K 0.21% 121
2018
Q4 		$210K Buy
+2,516
New +$236K 0.06% 218

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Kintegral Advisory's DGX Position: Q1 2026 in Review

Kintegral Advisory reduced its Quest Diagnostics (DGX) stake by 4.2% in Q1 2026, selling an estimated $103K and leaving 11,984 shares worth $2.35M. The position accounts for 0.22% of the portfolio, ranked #109.

Kintegral Advisory first reported a position in DGX in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.45M in Q3 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Kintegral Advisory held 11,984 shares of Quest Diagnostics worth $2.35M as of Q1 2026.
  • Kintegral Advisory sold 531 Quest Diagnostics shares in Q1 2026, an estimated $103K.
  • Quest Diagnostics made up 0.22% of Kintegral Advisory's portfolio in Q1 2026, its #109 holding.
  • Kintegral Advisory first reported a position in Quest Diagnostics in Q4 2018 and has held it in 30 quarters since.
  • Kintegral Advisory's Quest Diagnostics position peaked at $2.45M in Q3 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Kintegral Advisory's 13F filing for Q1 2026, filed 14 May 2026.